Aethlon Medical, Inc.

DB:EJU0 Stock Report

Market Cap: €5.2m

Aethlon Medical Valuation

Is EJU0 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of EJU0 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate EJU0's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate EJU0's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for EJU0?

Key metric: As EJU0 is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for EJU0. This is calculated by dividing EJU0's market cap by their current book value.
What is EJU0's PB Ratio?
PB Ratio0.9x
BookUS$6.02m
Market CapUS$5.52m

Price to Book Ratio vs Peers

How does EJU0's PB Ratio compare to its peers?

The above table shows the PB ratio for EJU0 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average1.8x
AUG Audientes
3.9xn/a€6.9m
GME Geratherm Medical
1.1x89.5%€23.6m
AAQ1 aap Implantate
1.6xn/a€22.4m
NN6 NanoRepro
0.5xn/a€19.7m
EJU0 Aethlon Medical
0.9x-4.5%€5.5m

Price-To-Book vs Peers: EJU0 is good value based on its Price-To-Book Ratio (0.9x) compared to the peer average (1.1x).

Price to Book Ratio vs Industry

How does EJU0's PB Ratio compare vs other companies in the DE Medical Equipment Industry?

2 CompaniesPrice / BookEstimated GrowthMarket Cap
MF6 MagForce
0.1x149.0%US$3.59m
MF6 MagForce
0.01xn/aUS$404.27k
No more companies available in this PB range
EJU0 0.9xIndustry Avg. 2.2xNo. of Companies2PB01.22.43.64.86+
2 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: EJU0 is good value based on its Price-To-Book Ratio (0.9x) compared to the European Medical Equipment industry average (2.2x).

Price to Book Ratio vs Fair Ratio

What is EJU0's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

EJU0 PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio0.9x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate EJU0's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst EJU0 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€0.34
€3.66
+989.9%
81.8%€6.66€0.67n/a2
Nov ’25€0.32
€6.42
+1,907.5%
0.7%€6.47€6.38n/a2
Oct ’25€0.38
€6.42
+1,599.5%
0.7%€6.47€6.38n/a2
Sep ’25€0.33
€6.42
+1,846.7%
0.7%€6.47€6.38n/a2
May ’25€1.24
€23.07
+1,760.8%
60.1%€36.94€9.21n/a2
Apr ’25€1.55
€23.07
+1,388.6%
60.1%€36.94€9.21n/a2
Mar ’25€1.56
€29.09
+1,764.5%
27.1%€36.97€21.20n/a2
Feb ’25€1.65
€29.09
+1,662.8%
27.1%€36.97€21.20n/a2
Jan ’25€1.93
€29.09
+1,407.0%
27.1%€36.97€21.20n/a2
Dec ’24€1.71
€29.09
+1,600.9%
27.1%€36.97€21.20n/a2
Nov ’24€1.36
€29.79
+2,098.3%
27.1%€37.86€21.71€0.322
Jul ’24€3.44
€64.94
+1,787.8%
28.6%€83.49€46.39€0.422
Jun ’24€2.81
€69.06
+2,357.7%
22.0%€84.22€53.90€0.332
May ’24€3.32
€69.06
+1,980.2%
22.0%€84.22€53.90€1.242
Apr ’24€3.41
€69.06
+1,925.9%
22.0%€84.22€53.90€1.552
Mar ’24€4.39
€69.06
+1,473.9%
22.0%€84.22€53.90€1.562
Feb ’24€4.97
€72.12
+1,349.9%
20.0%€86.54€57.70€1.652
Jan ’24€2.37
€72.12
+2,941.8%
20.0%€86.54€57.70€1.932
Dec ’23€3.97
€72.12
+1,715.7%
20.0%€86.54€57.70€1.712
Nov ’23€5.07
€61.61
+1,114.3%
30.9%€79.22€35.21€1.363

Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.

Discover undervalued companies

Shandong Weigao Group Medical Polymer

HK$20.6b

Engages in the research and development, production, wholesale, and sale of medical devices in the People’s Republic of China.

UK2

HK$0.53

7D

1.0%

1Y

-34.2%

LNA Santé

€234.2m

Engages in the management and operation of health establishments.

2N3

€22.30

7D

-4.9%

1Y

16.8%

Top Glove Corporation Bhd

RM 7.8b

An investment holding company, manufactures, trades in, and sells gloves in Malaysia, Thailand, the People’s Republic of China, and internationally.

5OU

RM 0.98

7D

0.5%

1Y

-82.5%